Rigshospitalet to evaluate CERAMENT™ platform for use in bone tumors
Two separate studies confirm efficacy of CERAMENT™|G, an antibiotic eluting bone substitute, as a new option in the surgical management of osteomyelitis in the infected diabetic foot.
Lund, Sweden, (PRNEWSWIRE) January 5, 2016 – BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced data from two studies confirming the efficacy of the Company’s CERAMENT™ antibiotic eluting bone substitute technology as a step in the management of osteomyelitis (OM) in infected diabetic foot. CERAMENT™|G, which releases Gentamicin, received CE-mark in 2013, and is the first approved antibiotic eluting bone substitute indicated to promote and protect bone healing in the management of bone infections.
93% of patients had full or partial cyst resolution at 12 months
• No post-operative infections reported during follow-up period
• No fractures reported during the follow-up period
Ness Ziona, Israel – Dec 7, 2015 – Atox Bio, developer of immunomodulatory therapeutics for rapidly-progressing infectious diseases in critically ill patients, today announced that it has enrolled the first patient in its Phase 3 study to evaluate AB103 – the first-ever candidate developed for the treatment of Necrotizing Soft Tissue Infections (NSTIs), also known as ‘flesh eating bacteria’. The ACCUTE (AB103 Clinical Composite
endpoint StUdy in necrotizing soft Tissue InfEctions) study is conducted at approximately 40 centers in the U.S. and expects to enroll 290 patients who will receive around the clock coverage by highly experienced surgical teams and critical care support.
|Forrige 1 2 3 4 5 6 7 8 9 10 Næste 10 Næste|